BREXANOLONE
| Brand name | ZULRESSO |
|---|---|
| Active ingredient | BREXANOLONE |
| Strength | 100MG/20ML (5MG/ML) |
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Modality | Small molecule |
| FDA approval | June 2019 |
| Marketing status | DISCN |
| Patent | Expires | Type |
|---|---|---|
| 10940156 | March 2037 | use U-2552 |
| 10251894 | November 2033 | use U-2552 |
| 10322139 | January 2033 | product |
| 9750822 | March 2029 | product |
| 7635773 | March 2029 | product |
| 10117951 | March 2029 | product |
| 8410077 | March 2029 | product |
| 9200088 | March 2029 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.